The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.70 (7.955%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.15
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 May 2017 14:47

RNS Number : 7114F
Scancell Holdings Plc
19 May 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Scancell Holdings plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Calculus Capital Limited

4. Full name of shareholder(s)  (if different from 3.):iv

Reyker Nominees/Investec Wealth and Investment

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

11 May 2017

6. Date on which issuer notified:

19 May 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

18%,17%,16%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

ISIN: GB00B63D3314

49,203,353

49,203,353

50,203,353

50,203,353

15.3%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

50,203,353

15.3%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

N/A

14. Contact name:

Calculus Capital Limited

15. Contact telephone number:

0207 493 4940

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFSVEEIALID
Date   Source Headline
27th Oct 20204:36 pmRNSPrice Monitoring Extension
26th Oct 202010:10 amRNSConversion of Convertible Loan Notes
21st Oct 20204:12 pmRNSNotice of Annual General Meeting
16th Oct 20207:00 amRNSFinal Results for the year ended 30 April 2020
15th Oct 202011:10 amRNSHolding(s) in Company
14th Oct 202011:36 amRNSHolding(s) in Company
13th Oct 202012:07 pmRNSPosting of Circular
12th Oct 20207:00 amRNSProposed investment by Redmile and Open Offer
5th Oct 20207:00 amRNSNotice of Final Results
2nd Oct 20207:00 amRNSCollaboration to manufacture COVID-19 vaccine
24th Sep 20207:00 amRNSDirectorate Change
14th Sep 20204:41 pmRNSSecond Price Monitoring Extn
14th Sep 20204:36 pmRNSPrice Monitoring Extension
14th Sep 20209:05 amRNSSecond Price Monitoring Extn
14th Sep 20209:00 amRNSPrice Monitoring Extension
11th Sep 20204:41 pmRNSSecond Price Monitoring Extn
11th Sep 20204:35 pmRNSPrice Monitoring Extension
8th Sep 20204:40 pmRNSSecond Price Monitoring Extn
8th Sep 20204:35 pmRNSPrice Monitoring Extension
4th Sep 20207:00 amRNSDirector Award of Share Options
27th Aug 20207:00 amRNSFunds awarded by Innovate UK for COVID-19 vaccine
26th Aug 20204:02 pmRNSHolding(s) in Company
25th Aug 202010:11 amRNSHolding(s) in Company
12th Aug 20203:13 pmRNSHolding(s) in Company
12th Aug 202012:57 pmRNSDirector Dealing
11th Aug 202010:54 amRNSResults of General Meeting
23rd Jul 20204:44 pmRNSShareholder circular
22nd Jul 20201:51 pmRNSResult of Placing and Notice of General Meeting
22nd Jul 20207:00 amRNSProposed Capital Raise
24th Jun 20207:00 amRNSNew publication highlights potential of Modi-1
12th Jun 20209:30 amRNSPublication highlights potential of AvidiMab
1st May 20207:00 amRNSDirector salaries and award of share options
29th Apr 20202:06 pmRNSSecond Price Monitoring Extn
29th Apr 20202:00 pmRNSPrice Monitoring Extension
28th Apr 202010:06 amRNSDirector Dealing
27th Apr 20204:39 pmRNSDirector Dealing
24th Apr 20202:05 pmRNSSecond Price Monitoring Extn
24th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSScancell: Development of vaccine against COVID-19
16th Mar 20204:42 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
3rd Mar 20207:00 amRNSScancell to Present at Three Research Conferences
3rd Feb 20207:00 amRNSSCIB1 IND Application Approved
31st Jan 20207:00 amRNSInterim Results
20th Jan 20207:00 amRNSThird agreement signed for antibody platform
17th Dec 201912:44 pmRNSDirector's Dealings
16th Dec 20197:00 amRNSSecond agreement signed for AvidiMab platform
20th Nov 20197:00 amRNSNew European Moditope patent allowed for grant
23rd Oct 20197:00 amRNSDirectorate Change
26th Sep 20197:00 amRNSPosters at Cancer Immunotherapy Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.